MRNA
Moderna Stock Analysis - MRNAModerna (NASDAQ: MRNA).
The Major trend is Bullish; The Trendline and EMA (with a length of 200) has been broken giving a signal of weakness of this Market. The idea is always to invest in the trend direction (bullish), but currently there are not a lot of signals to go long.
If 66.5 USD level will not be broken in the next days, perhaps the idea is to go long, or, vice versa, if the support will be broken the idea is to go short (this option is too Risky).
Long and hold $GSK ($MRNA $GILD $INO $SPY $PFE $JNJ $MRK)see full chart at www.tradingview.com
GSK
Entry $39.70
Target 1 $42.45
Target 2 $45.50
Target 3 $48
stoploss 38.70
Why this play?
There are 4 general approaches to the Covid vaccine.
1.A "killed" coronavirus that will get recognized as foreign matter in the blood. (Sinovac/Dynavax)
2.Coronavirus proteins themselves, produced industrially in outside cell cultures,
which will be recognized as foreign matter in the blood. (GlaxoSmithKline/Sanofi, Novavax)
3.A different virus (human or ape adenovirus, measles, etc) that is engineered
to include genetic components coding for the SARS-CoV-2 spike proteins,
which causes the body to then produce them. (CanSino, Oxford, J&J,
Merck/Themis)
4.DNA or RNA that will be taken up by cells and will cause them to make
coronavirus proteins. (Moderna, Innovio,
BioNTech/Pfizer)
GSK is #2, there is only 1 other big company doing this approach and that is NVAX.
We are betting on the fact that if they are successful, they could have super run like NVAX.
What is GSk?
www.gsk.com
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Possible Positive Divergence for MRNA 1h chartHello everyone!!!
This time I brought another idea on MRNA, my feeling is still going LONG there is a possible positive divergence on MRNA 1h chart.
Also the stock has been respecting the trend line also we have a big support zone around 65 and 70 USD.
Please let me know you thoughts on this analysis and looking forward to hear from you guys!!!
Also if you want to read more about positive divergences.
www.investopedia.com
I really like divergences strategies because it's a really powerful reversal leading indicator.
www.ig.com
MRNA Buy now or neverI really like MRNA, the stock has been consolidating for some time now but if we take a look at the graph the next stop will be $100.00 where we have a big resistance that has been hit two times in the past.
Also I don't expect the stock to go any further down because there is a big support zone around $66.
Please let me know your thoughts on this analysis, looking forward to hear from you guys.
CREATIVE WAYSAccording to source, Pinterest has recently seen the highest searches ever around mental wellness ideas including meditation (+44%), gratitude (+60%) and positivity (+42%) that jumped from February to May. Pinners are looking for creative ways to navigate and cope with their “new normal,” so they took a closer look at their shifting priorities to understand which trends would live out the remainder of 2020.
$MRNA will run to $78.5, then $65I will be picking up puts at 78.5, 78-80 strike price with Friday expiry. ER aside this chart is setting up well from a short from the fib at $78.5. Additionally, RSI has not been below 40 at all this year. I also saw that the CMO dumped shares last week near the ath.
Moderna Stock Analysis - MRNAThe trend is bullish - the idea is to invest in the trend direction - wait the end of the price retracement before going long.
Moderna (MRNA) – Moderna is aiming to price its Covid-19 vaccine at $50 to $60 per dose, according to sources cited by the Financial Times. That would be at least $11 more than the vaccine being developed by Pfizer (PFE) and partner BioNTech (BNTX).
LONG $AZN Covid wave 2 play ($MRNA $GILD $INO $SPY)see full chart at www.tradingview.com
AZN
Entry $54 area
Target $57
stoploss 53
Why this play?
Covid Vaccine stocks are hot right now, cases are rising = easy money.
What is AZN?
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology,
cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide.
The company serves primary care and specialty care physicians through distributors and local representative offices.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
Analysis on Moderna (Vaccine Company)Moderna (MRNA) is developing a COVID-19 vaccine candidate that is widely considered one of the frontrunners to bring a vaccine to market; it was the first company to share data about how its experimental vaccine performed in a Phase 1 clinical trial. It has so far soared more than 350% since the start of the year. The main reason is that there has been tremendous widespread investor interest on their vaccination project, and the obvious unmet need/opportunity for a COVID-19 vaccine. However, J.P. Morgan just recently downgraded the rating on Moderna (MRNA) and signal that its currently overvalued. I feel that if the price dips or there's any pullback, would be a good opportunity to enter for a short hold and probably selling it upon the next peak which I believe would be around their Phase 3 trials. Because long term hold on Moderna might be risky since more often than not, vaccines usually takes a long time before it actually gets released and for the company to be actually profitable.